2015-04-02
Low doses of the anti-cancer drug imatinib can spur the bone marrow to produce more innate immune cells to fight against bacterial infections, Emory researchers have found. The results were published March 30, 2015 in the journal PLOS Pathogens. The findings suggest imatinib, known commercially as Gleevec, or related drugs could help doctors treat